Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Clinical Trial of the Efficacy and Safety of Tislelizumab in Combination With BCG Bladder Instillation in the Prevention of Postoperative Recurrence in Intermediate and High-risk Non-muscle Invasive Bladder Cancer

NCT06441110 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT06441110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Clinical Trial of the Efficacy and Safety of Tislelizumab in Combination With BCG Bladder Instillation in the Prevention of Postoperative Recurrence in Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Lead sponsor
Fujian Medical University Union Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
June 1, 2023
Completion date
June 1, 2035
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bcg vaccine, immunotherapy, active, multicenter study, neoplasm recurrence, local, treatment outcome, urinary bladder neoplasms